Probiotics-Driven Type I Photosensitizer for Tumor-Targeted Fluorescence Imaging and Photodynamic Immunotherapy
Analytical Chemistry · 2026
DOI: 10.1021/acs.analchem.6c04528 ↗Kurz gefasst
Fachartikel in der Zeitschrift Analytical Chemistry, 2026. Verfasst von Jiayi Zhao und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Life Science, Sichuan University, Chengdu610064, China. Hauptthemen laut MEDLINE: Photosensitizing Agents, Photochemotherapy, Optical Imaging, Immunotherapy. Die Arbeit nennt 45 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China (NSFC).
Abstract (Originalsprache)
The high morbidity and mortality of cancer have driven the medical community to continuously explore strategies for diagnosis and treatment. Photosensitizers (PSs) offer the possibility of simultaneous diagnosis and photodynamic therapy (PDT) for tumors with the advantages of noninvasiveness, high sensitivity, and minimum drug resistance. However, current PSs lack active tumor-targeting capability and systemic antitumor immune activity, leading to poor diagnostic and therapeutic efficacy, which remains a major challenge in cancer theranostics. To address this issue, a boric acid-functionalized type I PS-engineered probiotic (E. coli@ACR-DMP) was developed for tumor-targeted fluorescence diagnosis and photodynamic immunotherapy. This system leverages the natural tumor hypoxia tropism of Escherichia coli (E. coli) for driving tumor targeting and further responds to the acidic tumor microenvironment to trigger PS release for fluorescence diagnosis and photodynamic ablation of the tumor. Furthermore, the pathogen-associated molecular patterns (PAMPs) synergize with PDT-induced immunogenic cell death to promote dendritic cell maturation and T-cell infiltration, converting local phototherapy into systemic antitumor immune activation. In a 4T1 tumor-bearing mouse model, E. coli@ACR-DMP exhibits excellent tumor-targeting ability, which enables its use in tumor fluorescence diagnosis and photodynamic inhibition of tumor growth along with activated antitumor immunity. This work provides a covalent bacteria-based delivery platform, offering a promising strategy for precision cancer therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- College of Life Science, Sichuan University, Chengdu610064, China.
- School of Life Science and Engineering, Southwest Jiaotong University, Chengdu610031, China.
- College of Biomedical Engineering, Sichuan University, Chengdu610064, China.
ORCID-Profile: Shun Feng, Ming-Yu Wu
Förderung
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China (NSFC)
Zitieren
APA
Zhao, J., Pan, X., Chen, Y., Feng, S., & Wu, M. Y. (2026). Probiotics-Driven Type I Photosensitizer for Tumor-Targeted Fluorescence Imaging and Photodynamic Immunotherapy. Analytical Chemistry. https://doi.org/10.1021/acs.analchem.6c04528
Vancouver
Zhao J, Pan X, Chen Y, Feng S, Wu MY. Probiotics-Driven Type I Photosensitizer for Tumor-Targeted Fluorescence Imaging and Photodynamic Immunotherapy. Analytical Chemistry. 2026. doi:10.1021/acs.analchem.6c04528
BibTeX
@article{Zhao2026,
author = {Zhao, Jiayi and Pan, Xiu and Chen, Yuan and Feng, Shun and Wu, Ming-Yu},
title = {Probiotics-Driven Type I Photosensitizer for Tumor-Targeted Fluorescence Imaging and Photodynamic Immunotherapy},
journal = {Analytical Chemistry},
year = {2026},
doi = {10.1021/acs.analchem.6c04528}
}
EUVIMED